跳至主要内容
临床试验/NCT04955808
NCT04955808
暂停
不适用

Early Onset Malignancies Initiative (EOMI): Molecular Profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate Among Racially and Ethnically Diverse Populations

National Cancer Institute (NCI)1 个研究点 分布在 1 个国家目标入组 2,400 人2017年2月7日

概览

阶段
不适用
干预措施
Biospecimen Collection
疾病 / 适应症
Breast Carcinoma
发起方
National Cancer Institute (NCI)
入组人数
2400
试验地点
1
主要终点
Acquisition of tissue, blood, and other biospecimens for research purposes
状态
暂停
最后更新
19天前

概览

简要总结

This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery. Studying samples collected during surgery may add to the understanding of cancer by looking for the genetic changes that cause early cancer onset in people of certain racial and ethnic groups.

详细描述

PRIMARY OBJECTIVE: I. To acquire tissue and blood, and other biospecimens for research purposes during procedures for clinical care to accelerate our understanding of the molecular basis of early onset cancers occurring in racial and/or ethnic minority populations through the application of genome analysis technologies, including large- scale genome sequencing and clinical data analysis. OUTLINE: Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing. After completion of study, patients are followed for up at 6 and 12 months.

注册库
clinicaltrials.gov
开始日期
2017年2月7日
结束日期
2026年12月31日
最后更新
19天前
研究类型
Observational
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Patients with either:
  • Histologically confirmed invasive carcinoma or multiple myeloma OR
  • Clinical diagnosis of carcinoma or multiple myeloma OR
  • Suspected clinical diagnosis of multiple myeloma
  • Patients with one of following tumor types and age ranges:
  • Breast cancer diagnosis at ages 18-45
  • Colon cancer diagnosis at ages 18-55
  • Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native \[AIAN\] and non-Hispanic Whites \[NHW\] only)
  • Liver cancer diagnosis at ages 18-55
  • Prostate cancer diagnosis at ages 18-55

排除标准

  • Patients who do not meet criteria for an early onset malignancy
  • Prior systemic therapy or radiation therapy for their malignancy
  • Tumor does not meet quality metrics
  • Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative
  • A diagnosis of a synchronous invasive malignancy
  • Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years

研究组 & 干预措施

Ancillary-correlative (biospecimen collection)

Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.

干预措施: Biospecimen Collection

Ancillary-correlative (biospecimen collection)

Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.

干预措施: Laboratory Biomarker Analysis

结局指标

主要结局

Acquisition of tissue, blood, and other biospecimens for research purposes

时间窗: Up to 3 years

Will be performed.

研究点 (1)

Loading locations...

相似试验